Adam V Patterson
Overview
Explore the profile of Adam V Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toscan C, McCalmont H, Ashoorzadeh A, Lin X, Fu Z, Doculara L, et al.
Blood Cancer J
. 2024 Nov;
14(1):192.
PMID: 39505850
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed...
2.
Sharrock A, Mumm J, Williams E, cenas N, Smaill J, Patterson A, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928299
Bacterial nitroreductase enzymes capable of activating imaging probes and prodrugs are valuable tools for gene-directed enzyme prodrug therapies and targeted cell ablation models. We recently engineered a nitroreductase ( NfsB...
3.
Yang F, Lin Q, Song X, Huang H, Chen X, Tan J, et al.
J Med Chem
. 2024 Feb;
67(4):2667-2689.
PMID: 38348819
Fibroblast growth factor receptor 4 (FGFR4) has been considered as a potential anticancer target due to FGF19/FGFR4 mediated aberrant signaling in hepatocellular carcinoma (HCC). Several FGFR4 inhibitors have been reported,...
4.
Mowday A, van de Laak J, Fu Z, Henare K, Dubois L, Lambin P, et al.
Crit Rev Microbiol
. 2024 Feb;
50(6):955-970.
PMID: 38346140
Cancer immunotherapies have been widely hailed as a breakthrough for cancer treatment in the last decade, epitomized by the unprecedented results observed with checkpoint blockade. Even so, only a minority...
5.
Theys J, Patterson A, Mowday A
Mol Diagn Ther
. 2024 Feb;
28(2):141-151.
PMID: 38302842
Necrosis is a common feature of solid tumours that offers a unique opportunity for targeted cancer therapy as it is absent from normal healthy tissues. Tumour necrosis provides an ideal...
6.
Ashoorzadeh A, Mowday A, Abbattista M, Guise C, Bull M, Silva S, et al.
ACS Med Chem Lett
. 2023 Nov;
14(11):1517-1523.
PMID: 37974941
Off-target aerobic activation of PR-104A by human aldo-keto reductase 1C3 (AKR1C3) has confounded the development of this dual hypoxia/gene therapy prodrug. Previous attempts to design prodrugs resistant to AKR1C3 activation...
7.
Chen H, Hu S, Patterson A, Smaill J, Ding K, Lu X
J Med Chem
. 2023 Sep;
66(17):11656-11671.
PMID: 37669428
Epidermal growth factor receptor (EGFR) targeted therapy is one of the most important and effective strategies to combat EGFR mutant nonsmall-cell lung cancer (NSCLC). However, a substantial number of patients...
8.
Yang F, Chen X, Song X, Ortega R, Lin X, Deng W, et al.
J Med Chem
. 2022 Oct;
65(21):14809-14831.
PMID: 36278929
The FGF19-FGFR4 signaling pathway has been extensively studied as a promising target for the treatment of hepatocellular carcinoma (HCC). Several FGFR4-selective inhibitors have been developed, but none of them receives...
9.
Xu F, Zhang X, Chen Z, He S, Guo J, Yu L, et al.
J Med Chem
. 2022 Sep;
65(20):14032-14048.
PMID: 36173763
EGFR inhibitor therapies have brought significant benefit to NSCLC patients. However, all patients gradually progress to acquired resistance diverse mechanisms. Akt3 overexpression but not Akt1/2 is one of the found...
10.
Shao M, Chen X, Yang F, Song X, Zhou Y, Lin Q, et al.
J Med Chem
. 2022 Mar;
65(6):5113-5133.
PMID: 35271262
Aberrant FGF19/FGFR4 signaling has been shown to be an oncogenic driver of growth and survival in human hepatocellular carcinoma (HCC) with several pan-FGFR inhibitors and FGFR4-selective inhibitors currently being evaluated...